AI assistant
Boundless Bio, Inc. — Director's Dealing 2024
Mar 28, 2024
34838_dirs_2024-03-27_28b0935c-fbcf-4fbc-88c9-8fb58bc8a443.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Boundless Bio, Inc. (BOLD)
CIK: 0001782303
Period of Report: 2024-03-27
Reporting Person: Hassig Christian (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 25641 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $3.12 | 2029-12-02 | Common Stock (38461) | Direct | |
| Stock Option | $3.71 | 2030-12-01 | Common Stock (10256) | Direct | |
| Stock Option | $4.10 | 2031-06-06 | Common Stock (62820) | Direct | |
| Stock Option | $4.10 | 2033-06-12 | Common Stock (94871) | Direct | |
| Stock Option | $8.19 | 2034-02-14 | Common Stock (76173) | Direct |
Footnotes
F1: The stock option vests in substantially equal monthly installments until fully vested on October 28, 2024.
F2: The stock option vests as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 48 substantially equal monthly installments thereafter.
F3: The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021.
F4: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023.
F5: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.